The program’s legitimacy rests on transparency, audits, and ensuring benefits reach vulnerable patients.
Sruthi Katamneni, DDS, MBA, MHA
Advertisement
Articles by Sruthi Katamneni, DDS, MBA, MHA
Advertisement
Latest Updated Articles
Billions at Stake: 340B Program Integrity and Sustainability in 2024-2025Published: November 20th 2025 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel
5